Adrenomed's lead product candidate, Adrecizumab, is a monoclonal antibody that targets the vasoprotective peptide Adrenomedullin to treat life-threatening conditions associated with increased vascular leakage, congestion, and shock. Their unique approach combines the therapeutic antibody with a specific diagnostic that uses Adrenomedullin as the biomarker to identify patients. Adrenomed's business is secured by strong IP position with granted patents in all major markets. The company's focus is on sepsis, septic shock, and acute heart failure, and Adrecizumab has successfully completed a Phase II trial with 301 patients suffering from septic shock.